CytRx (CYTR) to Initiate Phase 2 Proof-of-Concept Trial to Evaluate Efficacy/Safety of Bafetinib
Tweet Send to a Friend
CytRx Corporation (NASDAQ: CYTR) today announced plans to initiate a Phase 2 proof-of-concept clinical trial to evaluate the efficacy and ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
